

Richard A Wells

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11522666/publications.pdf>

Version: 2024-02-01

79
papers

2,425
citations

304743

22
h-index

206112

48
g-index

80
all docs

80
docs citations

80
times ranked

3161
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of miR-145 and miR-146a as mediators of the 5q ⁻ syndrome phenotype. <i>Nature Medicine</i> , 2010, 16, 49-58.	30.7	588
2	Fusion of retinoic acid receptor β to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. <i>Nature Genetics</i> , 1997, 17, 109-113.	21.4	276
3	Tet2 restrains inflammatory gene expression in macrophages. <i>Experimental Hematology</i> , 2017, 55, 56-70.e13.	0.4	210
4	An inflammatory environment containing TNF β favors Tet2-mutant clonal hematopoiesis. <i>Experimental Hematology</i> , 2018, 59, 60-65.	0.4	141
5	Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an <i>International Myeloid Malignancy Consortium</i> (IMM-C) prospective study. <i>British Journal of Haematology</i> , 2016, 174, 88-101.	2.5	78
6	Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. <i>Annals of Hematology</i> , 2008, 87, 345-352.	1.8	76
7	Telomere-related sequences at interstitial sites in the human genome. <i>Genomics</i> , 1990, 8, 699-704.	2.9	72
8	Progression of myelodysplasia to acute lymphoblastic leukaemia: Implications for disease biology. <i>Leukemia Research</i> , 2006, 30, 233-239.	0.8	69
9	Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. <i>Blood Advances</i> , 2018, 2, 2176-2185.	5.2	65
10	Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. <i>Oncogene</i> , 1999, 18, 633-641.	5.9	59
11	Cross-Talk between PPARs and the Partners of RXR: A Molecular Perspective. <i>PPAR Research</i> , 2009, 2009, 1-9.	2.4	54
12	Multiple variants in subtelomeric regions of normal karyotypes. <i>Genomics</i> , 1992, 14, 1019-1025.	2.9	52
13	Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: A retrospective study of 322 bone marrows. <i>Leukemia Research</i> , 2009, 33, 1313-1318.	0.8	51
14	Iron overload in myelodysplastic syndromes: A Canadian consensus guideline. <i>Leukemia Research</i> , 2008, 32, 1338-1353.	0.8	49
15	Overall survival in lower <i>International Prognostic Scoring System</i> (IPSS) risk <i>Myelodysplastic Syndromes</i> (MDS) by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an <i>International Myeloid Malignancy Consortium</i> (IMM-C) analysis. <i>British Journal of Haematology</i> , 2017, 179, 83-97.	2.5	48
16	First among equals: The cancer cell hierarchy. <i>Leukemia and Lymphoma</i> , 2006, 47, 2017-2027.	1.3	44
17	Generation of high-titer viral preparations by concentration using successive rounds of ultracentrifugation. <i>Journal of Translational Medicine</i> , 2011, 9, 137.	4.4	43
18	How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry. <i>European Journal of Haematology</i> , 2019, 102, 36-52.	2.2	41

#	ARTICLE	IF	CITATIONS
19	Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RAR $\hat{\pm}$. <i>Oncogene</i> , 2004, 23, 665-678.	5.9	38
20	Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. <i>British Journal of Haematology</i> , 2020, 191, 476-485.	2.5	38
21	Simultaneous genetic mapping of multiple human minisatellite sequences using DNA fingerprinting. <i>Genomics</i> , 1989, 5, 761-772.	2.9	34
22	5-Azacytidine in myelodysplastic syndromes: A clinical practice guideline. <i>Cancer Treatment Reviews</i> , 2011, 37, 160-167.	7.7	32
23	Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS. <i>Leukemia Research</i> , 2018, 74, 21-41.	0.8	21
24	Lenalidomide and metronomic melphalan for CMML and higher risk MDS: A phase 2 clinical study with biomarkers of angiogenesis. <i>Leukemia Research</i> , 2014, 38, 756-763.	0.8	20
25	Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2020, 136, 37-38.	1.4	16
26	Expression of NPM-RAR $\hat{\pm}$ fusion gene in hematopoietic cells confers sensitivity to troglitazone-induced apoptosis. <i>Oncogene</i> , 2003, 22, 6424-6435.	5.9	14
27	The aryl hydrocarbon receptor nuclear translocator (ARNT) modulates the antioxidant response in AML cells. <i>Leukemia Research</i> , 2013, 37, 1750-1756.	0.8	14
28	The orphan nuclear receptor Ear-2 (Nr2f6) is a novel negative regulator of T cell development. <i>Experimental Hematology</i> , 2014, 42, 46-58.	0.4	12
29	A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry. <i>Annals of Hematology</i> , 2017, 96, 2025-2029.	1.8	12
30	Iron Overload and Haematopoiesis in MDS: Does Blood Transfusion Promote Progression to AML?. <i>Blood</i> , 2008, 112, 2685-2685.	1.4	12
31	Iron Overload Accelerates Development of Leukaemia: Evidence From a Mouse Model. <i>Blood</i> , 2010, 116, 122-122.	1.4	12
32	Transfusion Dependence and Low Hemoglobin Have the Greatest Impact On Quality of Life (QOL) in MDS Patients - a Tertiary Care Cross Sectional and Longitudinal Study.. <i>Blood</i> , 2009, 114, 2500-2500.	1.4	10
33	The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study. <i>Leukemia Research</i> , 2019, 76, 76-81.	0.8	9
34	Treatment of Adult Acute Lymphoblastic Leukemia (ALL) with a Modified DFCI Pediatric Regimen - The Princess Margaret Experience.. <i>Blood</i> , 2006, 108, 1875-1875.	1.4	9
35	Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells. <i>Leukemia Research</i> , 2006, 30, 1447-1451.	0.8	8
36	Revised 15-item MDS-specific frailty scale maintains prognostic potential. <i>Leukemia</i> , 2020, 34, 3434-3438.	7.2	8

#	ARTICLE	IF	CITATIONS
37	Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies. <i>Blood</i> , 2018, 132, 626-626.	1.4	7
38	Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies. <i>Blood</i> , 2019, 134, 952-952.	1.4	7
39	Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study. <i>Blood</i> , 2021, 138, 66-66.	1.4	7
40	The orphan nuclear receptor EAR-2 (NR2F6) inhibits hematopoietic cell differentiation and induces myeloid dysplasia in vivo. <i>Biomarker Research</i> , 2018, 6, 36.	6.8	6
41	Intracellular ROS profile in hematopoietic progenitors of MDS patients: association with blast count and iron overload. <i>Hematology</i> , 2021, 26, 88-95.	1.5	6
42	Differential lineage-specific regulation of murine CD45 transcription by Oct-1 and PU.1. <i>Biochemical and Biophysical Research Communications</i> , 2006, 344, 146-154.	2.1	5
43	Initial transfusion intensity predicts survival in myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2014, 55, 2296-2300.	1.3	5
44	One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment. <i>Blood</i> , 2019, 134, 2231-2231.	1.4	5
45	The Orphan Nuclear Receptor NR2F6 Is a Novel Negative Regulator of T-Cell Development.. <i>Blood</i> , 2009, 114, 915-915.	1.4	4
46	Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study. <i>Blood</i> , 2015, 126, 1701-1701.	1.4	4
47	The Effects of Azacitidine On Quality of Life: A Prospective Longitudinal Assessment. <i>Blood</i> , 2012, 120, 4938-4938.	1.4	4
48	Manipulation of reciprocal salt bridges at the heterodimerization interface alters the dimerization properties of mouse RXR α and PPAR γ 1. <i>Biochemical and Biophysical Research Communications</i> , 2007, 358, 1080-1085.	2.1	3
49	Correlation among nuclear localization of NuMA-RAR α , deregulation of gene expression and leukemic phenotype of hCG-NuMA-RAR α transgenic mice. <i>Leukemia Research</i> , 2011, 35, 670-676.	0.8	3
50	Prognostic Performance of Frailty Measures in MDS Patients Treated with Hypomethylating Agents. <i>Blood</i> , 2019, 134, 4245-4245.	1.4	3
51	Screening Patients with Myelodysplastic Syndrome and Aplastic Anemia for Paroxysmal Nocturnal Hemoglobinuria Clones: A Retrospective Study,. <i>Blood</i> , 2011, 118, 3426-3426.	1.4	3
52	Prophylactic Rh and Kell Antigen Matching Significantly Decreases Rates of Alloimmunization in Transfusion Dependent MDS Patients. <i>Blood</i> , 2014, 124, 4297-4297.	1.4	3
53	Impact of Bone Marrow Fibrosis in MDS Patients Treated with Azacitidine. <i>Blood</i> , 2016, 128, 4339-4339.	1.4	3
54	Identification of Mir-145 and Mir-146a as Micrnas Involved in the Pathogenesis of 5q- Syndrome. <i>Blood</i> , 2008, 112, 853-853.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Disordered Expression of HIPK Family Members in MDS and AML.. Blood, 2004, 104, 4311-4311.	1.4	2
56	Myelodysplastic syndrome. Cmaj, 2016, 188, 751-751.	2.0	1
57	Ravulizumab in the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opinion on Orphan Drugs, 2020, 8, 257-264.	0.8	1
58	Nuclear Localization of the NuMA-RAR β /RXR β Complex Is Necessary for Leukemogenesis in hCG-NuMA-RAR β Transgenic Mice.. Blood, 2006, 108, 1403-1403.	1.4	1
59	Patient Related Factors Have an Independent Impact on Overall Survival in Myelodysplastic Syndrome Patients: A Report of the MDS-Can Registry. Blood, 2014, 124, 165-165.	1.4	1
60	Validation of the Nordic Scoring System for Erythropoietic Stimulating Agents in MDS Using IWG 2006 Erythroid Response Criteria. Blood, 2012, 120, 1721-1721.	1.4	1
61	Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS. Blood, 2019, 134, 5416-5416.	1.4	1
62	Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study. Blood, 2021, 138, 3682-3682.	1.4	1
63	Iron overload in myelodysplastic syndromes. Expert Review of Hematology, 2009, 2, 215-218.	2.2	0
64	RXR β Null Haematopoietic Cells Fail To Reconstitute Haematopoiesis in Lethally Irradiated Recipient Mice.. Blood, 2004, 104, 2669-2669.	1.4	0
65	Functional Assessment of the Mitochondrial Pathway of Caspase Activation in Patients with Acute Myeloid Leukemia (AML).. Blood, 2004, 104, 2995-2995.	1.4	0
66	EAR-2: Identification of a Gene Involved in Maintenance of Clonogenicity in Haematopoiesis.. Blood, 2004, 104, 3226-3226.	1.4	0
67	Characterization of a Hierarchy of Proliferative Ability in AML: Identification of a Role for NR2F6 in the Maintenance of the Undifferentiated State.. Blood, 2006, 108, 2539-2539.	1.4	0
68	Estimating the Prevalence of Myelodysplasia: A Retrospective Review of Bone Marrow Histopathology in 322 Cases of Unexplained Cytopenia(s) in a Teaching Hospital.. Blood, 2006, 108, 2613-2613.	1.4	0
69	NR2F6, the Mammalian Homologue of Drosophila Seven Up, Can Initiate Myelodysplasia and Acute Leukemia.. Blood, 2007, 110, 400-400.	1.4	0
70	NR2F6 Initiates Myelodysplasia and Acute Leukemia by Promoting Stem Cell Self-Renewal. Blood, 2008, 112, 3655-3655.	1.4	0
71	Validation of a Scoring System to Establish the Pretest Probability of Myelodysplastic Syndrome in Patients with Unexplained Cytopenias or Macrocytosis.. Blood, 2009, 114, 1761-1761.	1.4	0
72	ARNT/HIF-1 β : An AML Biomarker?. Blood, 2010, 116, 2903-2903.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Arginase and YKL-40, Effectors of Immunosuppressive Myeloid Cells, Are Over-Expressed In the Bone Marrow of Most Chronic Myelomonocytic Leukemia Patients, and Are Potential Prognostic Biomarkers In Myelodysplastic Syndrome. Blood, 2010, 116, 1855-1855.	1.4	0
74	Initial Transfusion Rate Predicts Survival in MDS. Blood, 2011, 118, 2791-2791.	1.4	0
75	Utilization and Costs of Red Blood Cell Transfusions Pre- and Post-Azacitidine in Higher-Risk Myelodysplastic Syndromes. Blood, 2012, 120, 4261-4261.	1.4	0
76	Diffron C, a Novel Oligonucleotide Based Gene-Silencing Agent, Induces Terminal Differentiation in Primary Murine Cells. Blood, 2015, 126, 4122-4122.	1.4	0
77	Microenvironmental Links Between TET2/DNMT3A Mutations and Arginase 1 Overexpression in Human MDS/CMML. Blood, 2016, 128, 3164-3164.	1.4	0
78	Quality of Life Scores Improve with Increasing Hemoglobin but Optimal Thresholds Vary According to Transfusion Dependence and Clinical Risk Scores: A Canadian Cross Sectional Study of 689 Patients with 2969 Measurements. Blood, 2016, 128, 3192-3192.	1.4	0
79	Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab. Blood, 2018, 132, 625-625.	1.4	0